Meeting
2023 ASCO Genitourinary Cancers Symposium
Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
Authors
Daniela V. Castro
City of Hope Comprehensive Cancer Center, Duarte, CA
Daniela V. Castro , Matthew I. Feng , Sweta R. Prajapati , Elyse H. Chan , Kyle O. Lee , Ishaan Sehgal , Jalen Patel , Anna O'Dell , Zeynep Busra Zengin , Xiaochen Li , Alex Chehrazi-Raffle , Nazli Dizman , Abhishek Tripathi , Adam Rock , Sandy Liu , Benjamin D. Mercier , Luis A Meza , Errol James Philip , Tanya B. Dorff , Sumanta Monty Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Cancer Disparities
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 453)
DOI
10.1200/JCO.2023.41.6_suppl.453
Abstract #
453
Poster Bd #
G13
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
First Author: Matthew I. Feng
Poster
2024 ASCO Genitourinary Cancers Symposium
Validity of renal function eligibility criteria for cisplatin-based chemotherapy for patients with urothelial carcinoma.
First Author: Sai Hi
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
First Author: Evangelia Vlachou
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou